Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients
1 other identifier
interventional
30
1 country
1
Brief Summary
Prolactinoma is the most prevalent anterior hypophysis tumor. The principal treatment for this disorder is Dopamine agonist drugs including bromocriptin and Cabergoline. However, 50% of Bromocriptin treated and 17% of Cabergoline treated patients are resistant to these drugs. Curcumin is the main derivative of turmeric ,an old spice which is used frequently in Indian and Iranian cuisine. It has been proved that curcumin can reduce mammotrope cells proliferation and also intracellular hormone production. The purpose of this study is to evaluate the effect of turmeric on prolactinoma patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_1
Started Jul 2011
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 18, 2011
CompletedFirst Posted
Study publicly available on registry
April 29, 2011
CompletedStudy Start
First participant enrolled
July 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2012
CompletedNovember 1, 2011
October 1, 2011
1 year
April 18, 2011
October 29, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
serum prolactin level
2weeks and one month after treatment
Secondary Outcomes (1)
change in LH,FSH and estradiol from baseline
one month ofter treatment
Interventions
Curcumin is prescribed to new cases of hyperprolactinoma
Eligibility Criteria
You may qualify if:
- hyperprolactinemia
- microprolactinoma
You may not qualify if:
- pregnancy
- macroadenoma
- neurologic signs due to tumor
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Mashad University of Medical Sciences
Mashhad, Khorasan Razavi, Iran
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- assisstant professor
Study Record Dates
First Submitted
April 18, 2011
First Posted
April 29, 2011
Study Start
July 1, 2011
Primary Completion
July 1, 2012
Study Completion
August 1, 2012
Last Updated
November 1, 2011
Record last verified: 2011-10